Gilead Sciences, Inc. $GILD Shares Sold by ABN AMRO Bank N.V.

ABN AMRO Bank N.V. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.2% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 195,724 shares of the biopharmaceutical company’s stock after selling 27,117 shares during the period. ABN AMRO Bank N.V.’s holdings in Gilead Sciences were worth $27,521,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Traveka Wealth LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at approximately $229,000. Union Bancaire Privee UBP SA boosted its position in Gilead Sciences by 7.3% during the 1st quarter. Union Bancaire Privee UBP SA now owns 15,160 shares of the biopharmaceutical company’s stock worth $2,113,000 after acquiring an additional 1,031 shares during the period. Sterling Capital Management LLC boosted its position in Gilead Sciences by 25.4% during the 1st quarter. Sterling Capital Management LLC now owns 66,500 shares of the biopharmaceutical company’s stock worth $9,268,000 after acquiring an additional 13,470 shares during the period. Cambient Family Office LLC grew its stake in shares of Gilead Sciences by 4.7% in the first quarter. Cambient Family Office LLC now owns 9,573 shares of the biopharmaceutical company’s stock worth $1,334,000 after purchasing an additional 431 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its holdings in shares of Gilead Sciences by 9.8% during the first quarter. Venturi Wealth Management LLC now owns 4,179 shares of the biopharmaceutical company’s stock valued at $582,000 after purchasing an additional 374 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the transaction, the chief executive officer directly owned 617,567 shares in the company, valued at $81,185,357.82. This represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 68,000 shares of company stock worth $8,930,150 in the last three months. 0.30% of the stock is currently owned by insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Trodelvy won first-line approval in the U.S. and Europe for metastatic triple-negative breast cancer, opening a larger treatment market and improving Gilead’s oncology growth profile. Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and $155 price target after positive HIV trial results, signaling continued analyst confidence in Gilead’s pipeline and longer-term earnings potential. Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results
• Positive Sentiment: Merck’s FDA announcement that KEYTRUDA combinations can be used with Trodelvy in first-line advanced TNBC adds another validation point for Trodelvy’s role in frontline cancer care. FDA Approves KEYTRUDA and KEYTRUDA QLEX each with Trodelvy as First-Line Treatment of Advanced Triple-Negative Breast Cancer
• Neutral Sentiment: Recent coverage also noted Gilead’s stock had been drifting lower before the approval news, reflecting recent market weakness rather than a change in fundamentals. Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on GILD shares. Royal Bank Of Canada restated a “sector perform” rating on shares of Gilead Sciences in a research note on Monday, June 8th. Truist Financial reiterated a “buy” rating and issued a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Jefferies Financial Group started coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They set a “buy” rating and a $180.00 target price on the stock. Leerink Partners dropped their price target on shares of Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Finally, Daiwa Securities Group reduced their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Twenty-five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $158.41.

Gilead Sciences Stock Up 3.3%

NASDAQ GILD opened at $127.86 on Friday. Gilead Sciences, Inc. has a 12 month low of $106.84 and a 12 month high of $157.29. The company has a market capitalization of $158.75 billion, a P/E ratio of 17.42 and a beta of 0.31. The company’s 50 day simple moving average is $130.19 and its 200 day simple moving average is $134.28. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.